International: +1-347-960-6455
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis 2018

Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10135 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Others
Select License Type

Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke. A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature cardiovascular diseases. About 1 in 250 people around the world have HeFH and only about 10% of people with this medical condition have been diagnosed. Diagnosis is important because there are several early aggressive treatments available which can lower the risk for heart diseases or stroke.

The drug candidates of HeFH pipeline include, but not limited to, GEM-201 and anacetrapib. Some of the other companies having drugs in the HeFH pipeline includes Gemphire Therapeutics Inc. and Merck & Co. Inc.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.